Chinese expert consensus on clinical application of inhibitors of mammalian target of rapamycin in liver transplant recipients (2023 edition)
10.3969/j.issn.1674-7445.2023167
- VernacularTitle:肝移植受者雷帕霉素靶蛋白抑制剂临床应用中国专家共识（2023版）
- Author:
Feng HUO
1
;
Xiao XU
2
;
Qifa YE
3
;
Wujun XUE
Author Information
1. General Hospital of Southern Theater Command of PLA, Guangzhou 510010, China
2. Zhejiang University School of Medcine, Hangzhou 310003, China
3. Zhongnan Hospital of Wuhan University, Wuhan 430026, China
- Collective Name:COMMITTEE OF HEALTH MANAGEMENT FOR ORGAN TRANSPLANT RECIPIENT OF CHINA ORGAN TRANSPLANTATION DEVELOPMENT FOUNDATION;BRANCH OF ORGAN TRANSPLANT PHYSICIANS OF CHINESE MEDICAL DOCTOR ASSOCIATION;BRANCH OF ORGAN TRANSPLANT OF CHINESE MEDICAL ASSOCIATION, NATIONAL CENTER FOR HEALTHCARE QUALITY MANAGEMENT IN LIVER TRANSPLANT
- Publication Type:Journal Article
- Keywords:
Liver transplantation;
Immunosuppression;
Rapamycin;
Sirolimus;
Everolimus;
Tumor recurrence
- From:
Organ Transplantation
2023;14(6):765-780
- CountryChina
- Language:Chinese
-
Abstract:
The long-term survival and quality of life of liver transplant recipients largely depend on long-term health management and immunosuppression regimen after surgery. Long-term use of immunosuppressants may lead to severe complications, such as kidney injury, metabolic diseases and new malignant tumors, and even increase the risk of liver cancer recurrence after liver transplantation. At present, common immunosuppressive regimens in liver transplant recipients are delivered based on calcineurin inhibitor (CNI). However, renal toxicity, neurotoxicity and increased tumor recurrence caused by CNI have significantly affected clinical prognosis of the recipients. In recent years, the dosage of CNI has been gradually reduced and alternative drugs have been explored. Recently, the use of immunosuppressive regimens based on mammalian target of rapamycin inhibitor (mTORi) has been gradually increased. Multiple domestic and international guidelines have provided guidance on the use of mTORi in liver transplant recipients. China Organ Transplantation Development Foundation organized experienced transplant experts in China, combined with published guidelines, consensus and research progress at home and abroad and solicited extensive opinions to jointly formulate this expert consensus, aiming to provide reference for liver transplant clinicians in China.
